Company Market Research Report: Gameto

Company Overview

Name: Gameto

Mission: To redefine women’s health by developing transformational treatment solutions that improve women’s reproductive health throughout their lives.

Founded By: No information is available

Key People:

Dina Radenkovic, Co-founder & Chief Executive Officer

Christian Kramme, Chief Scientific Officer

Agustina Imfeld, Counsel & Chief Legal Officer

Gus Haddad, Chief Medical Officer

Emily Bosworth, Chief of Staff

Bruna Paulsen, VP of Manufacturing and Therapeutic Development

Other key personnel include Dr. Jaime Knopman, Dr. Ghassan (Gus) Haddad, and many scientific and clinical advisors.

Location: No information is available regarding the headquarters

Number of Employees: No information is available

Revenue: No information is available

What is the Company Known For: Gameto is renowned for its female-led approach in biotechnological advancements focused on improving women's reproductive health, notably in areas such as egg freezing, infertility, diseases of the reproductive years, menopause, and related conditions.

Products

Fertilo

Description: A lead investigational program designed to improve outcomes of IVF and other assisted fertility methods by employing minimal hormonal stimulation cycles and maturing eggs outside the body.

Key Features:

Engineered using ovarian support cells that replicate natural maturation.

Potentially cuts down IVF and egg freezing process from 14 days to just 3 days.

Aims to reduce necessary hormonal injections making treatments more accessible and safer.

Deovo

Description: A program focused on testing and developing drugs for ovarian diseases.

Key Features: No information is available

Ameno

Description: A program aimed at making the medical burdens of menopause optional.

Key Features:

Seeks to address root causes of menopausal symptoms and related post-menopausal health conditions.

Alleviates symptoms and long-term health risks such as cardiovascular and musculoskeletal disorders.

Recent Developments

Financial and Business Developments

Funding:

Gameto secured $33 million in Series B Financing to advance novel fertility treatments.

Received $23 million to redefine reproductive longevity with reprogrammed ovarian cells.

Selected to receive a $10 million award from ARPA-H’s Sprint for Women’s Health to accelerate research for the Ameno menopause program.

Product and Technology Development

Fertilo:

Demonstrated investigational product data showing high patient satisfaction compared to conventional fertility treatments.

Data on manufacturing process for its in vitro maturation solution presented at various scientific congresses.

Strategic Partnerships

Reprocell Partnership: A licensing agreement aimed at improving assisted fertility using induced pluripotent stem cells.

Stacey Bendet Collaboration: Launched the "Your Eggsperience Matters" campaign to raise funds during National Infertility Awareness Week.

Leadership and Advisory Appointments

Dr. Jaime Knopman: Appointed as Chairwoman of Clinical Advisory Board to guide clinical strategy and innovation.

Dr. Ghassan (Gus) Haddad: Appointed as Chief Medical Officer to oversee clinical development of Fertilo.

Other Advisors and Key Personnel: Includes collaboration with high-profile experts in reproductive medicine and genetic engineering.

Research and Recognition

Recognized as 2023 Technology Pioneer by the World Economic Forum for contributions to improving women's reproductive health.

Multiple presentations at international scientific meetings (e.g., ASRM, ESHRE) emphasizing advances in assisted reproductive technologies.

Conclusion

Gameto is actively reshaping the women’s health landscape through cutting-edge biotechnological solutions focused on fertility and menopause. Their commitment to pioneering therapeutic approaches is evident through substantial funding, strategic partnerships, a comprehensive product pipeline, and recognition in the industry, thereby positioning themselves as leaders in reproductive longevity and health innovation.